drugset / Trial / NCT05327296

Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)

NCT05327296 ↗

Phase 3 Completed 282 enrolled Sedana Medical
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.

Timeline

Start
2022-06-30
Primary completion
2024-05-28
Completion
2024-11-14

Outcome

Met primary endpoint

registry analysis (non-inferiority test); Isoflurane vs Propofol; p <.001; LS Mean difference -1.9; ANOVA NCT05327296 ↗

release “INSPiRE-ICU 2 has met its primary endpoint” sedanamedical.com ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Isoflurane Other / unclassified — Inhaled
Comparator Propofol Small molecule — Intravenous

Indications

No indication recorded.